Dibotatug for lymphoma, extranodal nk-t-cell

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 Jul 2022: Trial started, NCT05475925
  2. 27 Jul 2022: Trial registered, NCT05475925

The trials

NCT05475925: A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

State
Under way
Phase
Phase 1 and Phase 2
People
200 planned
Started
13 Jul 2022
Primary completion
Dec 2026
Arms
Part A Dose Escalation 1 mg/kg of DR-01, Part A Dose Escalation 3 mg/kg of DR-01, Part A Dose Escalation 6 mg/kg of DR-01, Part A Dose Escalation 10 mg/kg of DR-01, Part A Dose De-escalation 0.3 to <1 mg/kg of DR-01, Part B Dose Expansion (Cohort B1) Optimized Dose/Regimen of DR-01, Part B Dose Expansion (Cohort B2) Optimized Dose/Regimen of DR-01
Results
None posted
  1. 13 Jul 2022: Trial started
  2. 27 Jul 2022: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.